JPY 2,831.00
+28.00 (+1.00%)
JPY · as of 2026-08-18 · marketstack
| Size & multiples | |||
| Market Cap | JPY 2.52T | Enterprise Value | JPY 2.47T |
| P/E (TTM) | 11.74× | PEG (trailing) | 2.26× |
| P/S | 5.04× | P/FCF | 11.04× |
| EV/EBITDA | 12.74× | EV/EBIT | 14.80× |
| EV/Sales | 4.94× | EV/FCF | 10.82× |
| FCF Yield | 9.05% | Buyback Yield | — |
| Owner Earnings Yield | — | Shareholder Yield | — |
| Cost of capital & EVAmethodology → | |||
| Beta (5y monthly) | −0.18 | Risk-free (assumed) | 4.00% |
| Equity risk premium (assumed) | 4.23% | Cost of Equity | — |
| After-tax Cost of Debt | 1.12% | WACC | — |
| ROIC | — | EVA Spread (ROIC−WACC) | — |
| EVA | — | ||
Flows latest annual · EPS TTM JPY 241.04 · revenue TTM JPY 499.68B · FCF TTM JPY 228.04B (in JPY)
Output of a disclosed model — assumptions may be wrong. Research, not investment advice. See the Disclaimer.
| Metric | Today | Own median | Own range | %ile | z | Sector med. | mo · distinct |
|---|---|---|---|---|---|---|---|
| P/E | 11.63× | only 2 monthly observations — under the 12-month floor for a series line. P/E and EPS growth are reconstructed for US-domestic 10-K filers only — a 20-F/40-F foreign private issuer's ADR trades in USD while its EPS is reported in the native currency, so no multiple is reconstructed rather than a wrong one. | |||||
| 13.5% | — | no band (13 mo · 2 distinct) | — | — | −36.9% | 13 · 2 | |
| 11.0% | — | no band (13 mo · 2 distinct) | — | — | −15.4% | 13 · 2 | |
| 41.1% | — | no band (13 mo · 2 distinct) | — | — | −21.3% | 13 · 2 | |
| 17.1% | 10.1% | 55th | −0.12σ | 5.1% | 141 · 141 | ||
| EPS Growth 3Y | 5.2% | only 2 monthly observations — under the 12-month floor for a series line. P/E and EPS growth are reconstructed for US-domestic 10-K filers only — a 20-F/40-F foreign private issuer's ADR trades in USD while its EPS is reported in the native currency, so no multiple is reconstructed rather than a wrong one. | |||||
| 5.4% | — | no band (13 mo · 2 distinct) | — | — | 9.0% | 13 · 2 | |
| Market Cap | $15.67B | not reconstructed — market cap was removed from the historical pass (never a ranking factor, and a reconstructed share count carries look-ahead risk). The single stored value is the forward-captured snapshot, not a series. | |||||
shown for reference only — the reconstructed distribution did not clear the band gate, so no rank is quoted.
Filed earnings only.
no P/E ladder — only 2 monthly observations — under the 12-month floor for a series line. P/E and EPS growth are reconstructed for US-domestic 10-K filers only — a 20-F/40-F foreign private issuer's ADR trades in USD while its EPS is reported in the native currency, so no multiple is reconstructed rather than a wrong one.
Not a forecast: each row re-prices today's filed earnings at a multiple this company itself once traded at. It abstains rather than guess on a loss year or a broken per-share basis.
Every month uses only what was filed by then, split-adjusted. Delisted names are absent and a trough year can throw one huge reading, so read the median, not the edges.
Loading the monthly cohort placement…
Cheap vs Health Care on P/E, EV/EBITDA
P/E 19th · EV/EBITDA 38th pct
Whole-sector pool — median skews small.
| Metric | This (FY) | Peer median | IQR (25–75) | %ile |
|---|---|---|---|---|
| P/E | 11.6x | 26.0x | 13.7x–39.9x | 19 ↓cheap |
| EV/EBITDA | 12.6x | 15.9x | 9.9x–28.0x | 38 ↓cheap |
| EV/Sales | 4.9x | 3.3x | 1.7x–7.9x | 66 ↑rich |
| FCF Yield | 9.1% | -7.2% | -32.9%–1.4% | 93 ↑strong |
| Dividend Yield | 2.3% | 1.0% | 0.2%–2.4% | 72 ↑strong |
| Net Margin | 41.1% | -21.3% | -329.2%–7.1% | 97 ↑strong |
| Operating Margin | 33.4% | -34.7% | -552.6%–8.0% | 97 ↑strong |
| ROE | 13.5% | -36.9% | -92.5%–4.5% | 84 ↑strong |
Reading the covered industry pool…
Held-with peers…
Peers by disclosure language…
This company has no published industry pool year: either its industry group is untagged in our universe, we hold no annual revenue for it, or its group's newest year has not cleared the filing-alignment guard yet. This is a coverage gap, not a statement about the company.